Childhood and adult medulloblastoma: What difference?;Le médulloblastome de l'enfant et de l'adulte : quelle différence ?

Cancer/Radiotherapie

Volumn 13, Issue 6-7, 2009, Pages 530-535

  Padovani, L ^a   Andre N ^a   Carrie, C ^b   Muracciole, X ^a  

^a TIMONE HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Adults; Craniospinal irradiation; Medulloblastoma; Pediatric

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGE; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER STAGING; CHILD; CLINICAL PROTOCOL; DRUG SAFETY; HUMAN; MEDULLOBLASTOMA; NEUROSURGERY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SHORT SURVEY; TREATMENT INDICATION; ARTICLE; BRAIN TUMOR; CEREBELLUM TUMOR; COGNITIVE DEFECT; FRANCE; INCIDENCE; METHODOLOGY; MOLECULAR BIOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; SURGERY;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; COGNITION DISORDERS; COMBINED MODALITY THERAPY; FRANCE; HUMANS; INCIDENCE; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; RADIOTHERAPY; SURGICAL PROCEDURES, OPERATIVE;

EID: 70350706175     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2009.06.024     Document Type: Short Survey

References (56)

1. Aguiar P.H., Plese J.P., Ciquini O., and Marino R. Transient mutism following a posterior fossa approach to cerebellar tumors in children: a critical review of the literature. Childs Nerv Syst 11 (1995) 306-310
2. Albright A.L., Wisoff J.H., Zeltzer P.M., Boyett J.M., Rorke L.B., and Stanley P. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 38 (1996) 265-271
3. Allen J.C., Bloom J., Ertel I., Evans A., Hammond D., Jones H., et al. Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol 13 (1986) 110-122
4. Ashley D.M., Meier L., Kerby T., Zalduondo F.M., Friedman H.S., Gajjar A., et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14 (1996) 1922-1927
5. Bailey C.C., Gnekow A., Wellek S., Jones M., Round C., Brown J., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 25 (1995) 166-178
6. Bloom H.J., Wallace E.N., and Henk J.M. The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases. Am J Roentgenol 105 (1969) 43-62
7. Brandes A.A., Palmisano V., and Monfardini S. Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 25 (1999) 3-12
8. Brandes A.A., and Paris M.K. Review of the prognostic factors in medulloblastoma of children and adults. Crit Rev Oncol Hematol 50 (2004) 121-128
9. Brown H.G., Kepner J.L., Perlman E.J., Friedman H.S., Strother D.R., Duffner P.K., et al. Large cell/anaplastic medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59 (2000) 857-865
10. Carrie C., Grill J., Figarella-Branger D., Bernier V., Padovani L., Habrand J.L., et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98. J Clin Oncol 27 (2009) 1879-1883
11. Carrie C., Hoffstetter S., Gomez F., Moncho V., Doz F., Alapetite C., et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 45 (1999) 435-439
12. Chan A.W., Tarbell N.J., Black P.M., Louis D.N., Frosch M.P., Ancukiewicz M., et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 47 (2000) 623-631
13. Chang C.H., Housepian E.M., and Herbert Jr. C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93 (1969) 1351-1359
14. Chin D., Sklar C., Donahue B., Uli N., Geneiser N., Allen J., et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. Cancer 80 (1997) 798-804
15. Cochrane D.D., Gustavsson B., Poskitt K.P., Steinbok P., and Kestle J.R. The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 20 (1994) 19-29
16. Doz F. Tumeurs cérébrales malignes de l'enfant. Rev Prat 43 (1993) 2187-2191
17. Duffner P.K., Horowitz M.E., Krischer J.P., Friedman H.S., Burger P.C., Cohen M.E., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 (1993) 1725-1731
18. Duffner P.K., Krischer J.P., Horowitz M.E., Cohen M.E., Burger P.C., Friedman H.S., et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 44 (1998) 313-316
19. Eberhart C.G., Kepner J.L., Goldthwaite P.T., Kun L.E., Duffner P.K., Friedman H.S., et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94 (2002) 552-560
20. Entz-Werle N., Carli E.D., Ducassou S., Legrain M., Grill J., and Dufour C. Medulloblastoma: what is the role of molecular genetics?. Expert Rev Anticancer Ther 8 (2008) 1169-1181
21. Evans A.E., Jenkin R.D., Sposto R., Ortega J.A., Wilson C.B., Wara W., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 (1990) 572-582
22. Gajjar A., Chintagumpala M., Ashley D., Kellie S., Kun L.E., Merchant T.E., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 (2006) 813-820
23. Gajjar A., Hernan R., Kocak M., Fuller C., Lee Y., McKinnon P.J., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22 (2004) 984-993
24. Gajjar A., Sanford R.A., Bhargava R., Heideman R., Walter A., Li Y., et al. Medulloblastoma with brain stem involvement: the impact of gross total resection on outcome. Pediatr Neurosurg 25 (1996) 182-187
25. Gandola L., Massimino M., Cefalo G., Solero C., Spreafico F., Pecori E., et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 27 (2009) 566-571
26. Gentet J.C., Bouffet E., Doz F., Tron P., Roche H., Thyss A., et al. Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 82 (1995) 608-614
27. Gentet J.C., Doz F., Bouffet E., Plantaz D., Roche H., Tron P., et al. Carboplatin and VP 16 in medulloblastoma: a phase II Study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 23 (1994) 422-427
28. Jenkin D., Goddard K., Armstrong D., Becker L., Berry M., Chan H., et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 19 (1990) 265-274
29. Kalifa C., Hartmann O., Demeocq F., Vassal G., Couanet D., Terrier-Lacombe M.J., et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 9 (1992) 227-233
30. Kochbati L., Bouaouina N., Hentati D., Nasr C., Besbes M., Benna F., et al. Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors. Cancer Radiother 10 (2006) 107-111
31. Kovnar E.H., Kellie S.J., Horowitz M.E., Sanford R.A., Langston J.W., Mulhern R.K., et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 8 (1990) 330-336
32. Laughton S.J., Merchant T.E., Sklar C.A., Kun L.E., Fouladi M., Broniscer A., et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26 (2008) 1112-1118
33. Merchant T.E., Kun L.E., Krasin M.J., Wallace D., Chintagumpala M.M., Woo S.Y., et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23, 4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55. 8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 70 (2008) 782-787
34. Merchant T.E., Williams T., Smith J.M., Rose S.R., Danish R.K., Burghen G.A., et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 54 (2002) 45-50
35. Mulhern R.K., Palmer S.L., Merchant T.E., Wallace D., Kocak M., Brouwers P., et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23 (2005) 5511-5519
36. Muracciole X., and Regis J. Radiosurgery and carcinogenesis risk. Prog Neurol Surg 21 (2008) 207-213
37. Nicholson H.S., Kretschmar C.S., Krailo M., Bernstein M., Kadota R., Fort D., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110 (2007) 1542-1550
38. Oyharcabal-Bourden V., Kalifa C., Gentet J.C., Frappaz D., Edan C., Chastagner P., et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23 (2005) 4726-4734
39. Packer R.J., Gajjar A., Vezina G., Rorke-Adams L., Burger P.C., Robertson P.L., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 (2006) 4202-4208
40. Packer R.J., Goldwein J., Nicholson H.S., Vezina L.G., Allen J.C., Ris M.D., et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17 (1999) 2127-2136
41. Packer R.J., Sutton L.N., Elterman R., Lange B., Goldwein J., Nicholson H.S., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81 (1994) 690-698
42. Packer R.J., Sutton L.N., Goldwein J.W., Perilongo G., Bunin G., Ryan J., et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 74 (1991) 433-440
43. Padovani L., Sunyach M.P., Perol D., Mercier C., Alapetite C., Haie-Meder C., et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68 (2007) 433-440
44. Prados M.D., Warnick R.E., Wara W.M., Larson D.A., Lamborn K., and Wilson C.B. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys 32 (1995) 1145-1152
45. Rutkowski S., von Bueren A., von Hoff K., Hartmann W., Shalaby T., Deinlein F., et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13 (2007) 2651-2657
46. Schmiegelow M., Lassen S., Poulsen H.S., Feldt-Rasmussen U., Schmiegelow K., Hertz H., et al. Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin Endocrinol (Oxf) 53 (2000) 191-197
47. Segal R.A., Goumnerova L.C., Kwon Y.K., Stiles C.D., and Pomeroy S.L. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91 (1994) 12867-12871
48. Strojan P., Popovic M., and Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys 48 (2000) 65-73
49. Sunyach M., Padovani L., Carrie C., Alapetite C., and Aumont M. Adult medulloblastoma: What about the neurocognitive toxicity after craniospinal radiation?. Int J Radiat Oncol Biol Phys 72 (2009) S226
50. Tait D.M., Thornton-Jones H., Bloom H.J., Lemerle J., and Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26 (1990) 464-469
51. Thomas P.R., Deutsch M., Kepner J.L., Boyett J.M., Krischer J., Aronin P., et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 (2000) 3004-3011
52. Welzel G., Steinvorth S., and Wenz F. Cognitive effects of chemotherapy and/or cranial irradiation in adults. Strahlenther Onkol 181 (2005) 141-156
53. Wolden S.L., Dunkel I.J., Souweidane M.M., Happersett L., Khakoo Y., Schupak K., et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 21 (2003) 3079-3083
54. Xu W., Janss A., Packer R.J., Phillips P., Goldwein J., and Moshang Jr. T. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro Oncol 6 (2004) 113-118
55. Zeltzer P.M. Toward a cure for infants with brain tumours: the challenge for the 1990s. Br J Cancer Suppl 18 (1992) S41-S49
56. Zeltzer P.M., Boyett J.M., Finlay J.L., Albright A.L., Rorke L.B., Milstein J.M., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845